Purpose—To assess the feasibility of measuring symptomatic adverse events (AEs) in a multicenter clinical trial using the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Methods and Materials—Patients enrolled in Trial XXXX (XXXX) were asked to self-report 53 PRO-CTCAE items representing 30 symptomatic AEs at 6 time points (baseline; weekly x4 during treatment; 12-weeks post-treatment). Reporting was conducted via wireless tablet computers in clinic waiting areas. Compliance was defined as the proportion of visits when an expected PRO-CTCAE assessment was completed. Results—Among 226 study sites participating in Trial XXXX, 100% completed 35-minute PROCTCAE tra...
Symptomatic adverse events (AEs) in cancer trials are currently reported by clinicians using the Nat...
The National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria...
Background: Significant adverse events (AE) during cancer therapy disrupt treatment and escalate to ...
Purpose The US National Cancer Institute (NCI) Patient-Reported Outcomes version of the Common Termi...
ImportanceIn cancer clinical trials, symptomatic adverse events (AEs), such as nausea, are reported ...
IMPORTANCE: In cancer clinical trials, symptomatic adverse events (AEs), such as nausea, are reporte...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
Purpose There is increasing interest to use patient-reported outcome (PRO) measures to evaluate symp...
Understanding the potential profile of adverse events associated with cancer treatment is essential ...
Objective: The study sought to describe patient-entered supplemental information on symptomatic adve...
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials...
IMPORTANCE Standard adverse event (AE) reporting in oncology clinical trials has historically relied...
Background: The aim was to examine the feasibility, acceptability and clinical utility of electronic...
Systematic capture of the patient perspective can inform the development of new cancer therapies. Pa...
PURPOSE: Adverse event (AE) reporting is essential in clinical trials. Clinician interpretation can...
Symptomatic adverse events (AEs) in cancer trials are currently reported by clinicians using the Nat...
The National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria...
Background: Significant adverse events (AE) during cancer therapy disrupt treatment and escalate to ...
Purpose The US National Cancer Institute (NCI) Patient-Reported Outcomes version of the Common Termi...
ImportanceIn cancer clinical trials, symptomatic adverse events (AEs), such as nausea, are reported ...
IMPORTANCE: In cancer clinical trials, symptomatic adverse events (AEs), such as nausea, are reporte...
The National Cancer Institute (NCI) is developing a patient-reported version of its Common Terminolo...
Purpose There is increasing interest to use patient-reported outcome (PRO) measures to evaluate symp...
Understanding the potential profile of adverse events associated with cancer treatment is essential ...
Objective: The study sought to describe patient-entered supplemental information on symptomatic adve...
Symptomatic adverse events (AEs) are monitored by clinicians as part of all US-based clinical trials...
IMPORTANCE Standard adverse event (AE) reporting in oncology clinical trials has historically relied...
Background: The aim was to examine the feasibility, acceptability and clinical utility of electronic...
Systematic capture of the patient perspective can inform the development of new cancer therapies. Pa...
PURPOSE: Adverse event (AE) reporting is essential in clinical trials. Clinician interpretation can...
Symptomatic adverse events (AEs) in cancer trials are currently reported by clinicians using the Nat...
The National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria...
Background: Significant adverse events (AE) during cancer therapy disrupt treatment and escalate to ...